Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Enzyme Linked to Aggressive Prostate Cancer

By Labmedica International staff writers
Posted on 17 Jan 2013
The enzyme mesotrypsin, also known as protease, serine 3 (PRSS3), is specifically associated with aggressive prostate cancer risk.

Mesotrypsin appears to be an important mediator of prostate cancer progression and metastasis, and it has been suggested that inhibition of mesotrypsin activity may provide a novel modality for prostate cancer treatment.

Cancer biologists at the Mayo Clinic (Jacksonville, Florida, USA) explored whether any other cancer abnormally expresses the enzyme PRSS3 and when this occurred. They gathered and analyzed data from several sources. They used various techniques including cell culture, ribonucleic acid (RNA) extraction and polymerase chain reaction (PCR), bioluminescent imaging, and immunohistochemistry.

By transcriptional profiling, the investigators identified a correlation between PRSS3 gene expression and prostate cancer progression in a microarray dataset in which five benign prostate, five clinically localized prostate cancer, and five metastatic prostate cancer tissue specimens. They found that PRSS3 expression in tumors was strikingly associated with recurrence, defined as systemic progression or rising prostate specific antigen. The association of PRSS3 with prostate cancer metastasis, and the evidence that PRSS3 expression in primary tumors is prognostic of recurrence, suggest that mesotrypsin may play a critical functional role in prostate cancer progression.


Evette Radisky, PhD, the senior investigator, said, "This molecule is a protease, which means it digests other molecules. Our data suggests PRSS3 activity changes the environment around prostate cancer cells, perhaps by freeing them from surrounding tissue to promote malignancy and invasiveness. I do not think PRSS3 is the only factor involved in driving aggressive prostate cancer, but it may be significant for a certain subset of this cancer, the kind that is potentially lethal. Prostate cancer patients could be tested for the presence of the enzyme, so that doctors could identify which ones had the highest risk of metastasis." The study was published on December 17, 2012, in the journal Molecular Cancer Research.

Related Links:

Mayo Clinic



PERIPHERAL VISIONS INC
ADVANCED INSTRUMENTS
DiagCor Bioscience
comments powered by Disqus
Life Technologies

Channels

Genetic Tests

view channel
Image: Histopathology of Breast Adenocarcinoma, × 20 magnification (Photo courtesy of Nikon).

Serum Protein Biomarkers Detect Invasive Breast Cancer

The ability of serum protein biomarkers in conjunction with autoantibodies to distinguish between invasive breast cancer and benign breast conditions has been demonstrated. It has been estimated that... Read more

Industry News

view channel

Merck KGaA to Buy Sigma-Aldrich for USD 17 Billion

Merck KGaA (Darmstadt, Germany) will acquire Sigma-Aldrich (St. Louis, MO, USA) for USD 17 billion, expanding its business in North America and gaining exposure in Asia. All outstanding shares of Sigma-Aldrich will be acquired by Merck for USD 140 per share, which would represent a 37% premium to Sigma-Aldrich’s closing... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.